IL2 and acute myeloid leukemia: In AML patients treated with HDC plus IL-2, CD56dimCD16high NK cells displayed reduced expression of KIR, suggesting that the majority of these cells had just been differentiated from CD56bright cells and may not have yet acquired full KIR expression levels.